Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Long-Term Investments (2021 - 2023)

Historic Long-Term Investments for Cullinan Therapeutics (CGEM) over the last 3 years, with Q3 2023 value amounting to $15.5 million.

  • Cullinan Therapeutics' Long-Term Investments fell 4951.14% to $15.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $15.5 million, marking a year-over-year decrease of 4951.14%. This contributed to the annual value of $80.9 million for FY2022, which is 4239.05% down from last year.
  • As of Q3 2023, Cullinan Therapeutics' Long-Term Investments stood at $15.5 million, which was down 4951.14% from $20.3 million recorded in Q2 2023.
  • In the past 5 years, Cullinan Therapeutics' Long-Term Investments registered a high of $140.4 million during Q4 2021, and its lowest value of $15.5 million during Q3 2023.
  • Moreover, its 3-year median value for Long-Term Investments was $80.9 million (2022), whereas its average is $74.2 million.
  • Within the past 5 years, the most significant YoY rise in Cullinan Therapeutics' Long-Term Investments was 19709.45% (2022), while the steepest drop was 7530.76% (2022).
  • Over the past 3 years, Cullinan Therapeutics' Long-Term Investments (Quarter) stood at $140.4 million in 2021, then plummeted by 42.39% to $80.9 million in 2022, then plummeted by 80.84% to $15.5 million in 2023.
  • Its Long-Term Investments was $15.5 million in Q3 2023, compared to $20.3 million in Q2 2023 and $112.8 million in Q1 2023.